Ophthalmological screening guidelines for individuals with Osteogenesis Imperfecta: a scoping review.

Brittle bone disease Eye disease Eye manifestations Guidelines Knowledge synthesis Ocular manifestations Ophthalmology Optometry Osteogenesis imperfecta Prevention Review Screening

Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
30 Aug 2024
Historique:
received: 01 11 2023
accepted: 14 07 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 30 8 2024
Statut: epublish

Résumé

Osteogenesis imperfecta (OI) is a connective tissue disorder in which the Type 1 collagen is defective. The eye is a structure rich in collagen Type 1 and is heavily impacted by the disease. Many vision-threatening eye diseases have been associated with OI. The onset of these diseases also tend to occur at an earlier age in individuals with OI. Despite the research on these risks, appropriate ophthalmological screening or care guidelines for individuals with OI remain unknown. As such, the purpose of this scoping review was to explore and describe existing ophthalmological screening and care guidelines to orient OI patient care. A scoping review based on the Joanna Briggs Institute (JBI) methodology was conducted. A search of databases (PubMed and Medline) was completed in consultation with a research librarian. A total of 256 studies were imported for screening. Primary sources matching the inclusion and exclusion criteria were screened, extracted, and analyzed using Covidence. A total of 12 primary articles met inclusion and exclusion criteria, containing case reports, case series and cohort studies. Despite the risk of blindness associated with the consequences of OI on the eye, the primary literature fails to provide detailed screening and care guidelines aimed at identifying disease early. We provide general recommendations based on the review findings to guide the ophthalmological care of patients with OI and call upon the experts to convene globally to create screening guidelines. Further investigations of ophthalmological screening are warranted to limit these vision-threatening risks with early detection and treatment. Standardized ophthalmological screening guidelines for OI remain an area for research.

Sections du résumé

BACKGROUND BACKGROUND
Osteogenesis imperfecta (OI) is a connective tissue disorder in which the Type 1 collagen is defective. The eye is a structure rich in collagen Type 1 and is heavily impacted by the disease. Many vision-threatening eye diseases have been associated with OI. The onset of these diseases also tend to occur at an earlier age in individuals with OI. Despite the research on these risks, appropriate ophthalmological screening or care guidelines for individuals with OI remain unknown. As such, the purpose of this scoping review was to explore and describe existing ophthalmological screening and care guidelines to orient OI patient care.
MAIN BODY METHODS
A scoping review based on the Joanna Briggs Institute (JBI) methodology was conducted. A search of databases (PubMed and Medline) was completed in consultation with a research librarian. A total of 256 studies were imported for screening. Primary sources matching the inclusion and exclusion criteria were screened, extracted, and analyzed using Covidence.
CONCLUSION CONCLUSIONS
A total of 12 primary articles met inclusion and exclusion criteria, containing case reports, case series and cohort studies. Despite the risk of blindness associated with the consequences of OI on the eye, the primary literature fails to provide detailed screening and care guidelines aimed at identifying disease early. We provide general recommendations based on the review findings to guide the ophthalmological care of patients with OI and call upon the experts to convene globally to create screening guidelines. Further investigations of ophthalmological screening are warranted to limit these vision-threatening risks with early detection and treatment. Standardized ophthalmological screening guidelines for OI remain an area for research.

Identifiants

pubmed: 39215363
doi: 10.1186/s13023-024-03285-9
pii: 10.1186/s13023-024-03285-9
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

316

Informations de copyright

© 2024. The Author(s).

Références

Forlino A, Marini JC. Osteogenesis imperfecta. Lancet Lond Engl. 2016;387(10028):1657–71.
doi: 10.1016/S0140-6736(15)00728-X
Treurniet S, Burger P, Ghyczy EAE, Verbraak FD, Curro- Tafili KR, Micha D, et al. Ocular characteristics and complications in patients with osteogenesis imperfecta: a systematic review. Acta Ophthalmol (Copenh). 2022;100(1):e16–28.
doi: 10.1111/aos.14882
Chau FY, Wallace D, Vajaranant T, Herndon L, Lee P, Challa P et al. Chapter 31 - Osteogenesis imperfecta and the Eye. In: Shapiro JR, Byers PH, Glorieux FH, Sponseller PD, editors. Osteogenesis Imperfecta. San Diego: Academic Press; 2014 [cited 2022 Jan 17]. pp. 289–303. https://www.sciencedirect.com/science/article/pii/B9780123971654000319
Peters MD, Godfrey C, McInerney P, Munn Z, Tricco AC, Khalil H. Scoping reviews. Joanna Briggs Inst Rev Man. 2017;2015:1–24.
Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–73.
doi: 10.7326/M18-0850 pubmed: 30178033
Lyster ML, Hald JD, Rasmussen ML, Grauslund J, Folkestad L. Risk of eye diseases in osteogenesis imperfecta - A nationwide, register-based cohort study. Bone. 2022;154:116249.
doi: 10.1016/j.bone.2021.116249 pubmed: 34728432
Alpogan O. Association of osteogenesis imperfecta and glaucoma: case report. Ophthalmic Genet. 2022;0(0):1–5.
Bellanca RF, Scarinci F, Parravano M. Multimodal imaging in a young male with osteogenesis imperfecta complicated with choroidal neovascularization. Eur J Ophthalmol. 2020;30(1):NP21–4.
doi: 10.1177/1120672118811247 pubmed: 30409043
Correia Barão R, Santos M, Marques RE, Quintas AM, Guerra P. Keratoconus tomographic indices in osteogenesis imperfecta. Graefes Arch Clin Exp Ophthalmol. 2023 Apr 19 [cited 2023 Jun 4]; https://doi.org/10.1007/s00417-023-06059-4
Doolan E, O’Brien C. Abnormal corneal properties in osteogenesis imperfecta and glaucoma: a case series. BMJ Open Ophthalmol. 2021;6(1):e000684.
doi: 10.1136/bmjophth-2020-000684 pubmed: 33928192 pmcid: 8055117
Evereklioglu C, Madenci E, Bayazit YA, Yilmaz K, Balat A, Bekir NA. Central corneal thickness is lower in osteogenesis imperfecta and negatively correlates with the presence of blue sclera. Ophthalmic Physiol Opt. 2002;22(6):511–5.
doi: 10.1046/j.1475-1313.2002.00062.x pubmed: 12477015
Hald JD, Folkestad L, Swan CZ, Wanscher J, Schmidt M, Gjørup H, et al. Osteogenesis imperfecta and the teeth, eyes, and ears-a study of non-skeletal phenotypes in adults. Osteoporos Int. 2018;29(12):2781–9.
doi: 10.1007/s00198-018-4663-x pubmed: 30143849
Keleş A, Doğuizi S, Şahin NM, Koç M, Aycan Z. Anterior segment findings in patients with osteogenesis imperfecta: a case-control study. Cornea. 2020;39(8):935–9.
doi: 10.1097/ICO.0000000000002345 pubmed: 32355110
Oh EK, Choi HJ, Oh JY, Kim MK, Wee WR. Sequential traumatic and spontaneous corneal rupture in patient with osteogenesis imperfecta. Can J Ophthalmol. 2016;51(3):e81–4.
doi: 10.1016/j.jcjo.2016.01.001 pubmed: 27316285
Scollo P, Snead MP, Richards AJ, Pollitt R, DeVile C. Bilateral giant retinal tears in osteogenesis imperfecta. BMC Med Genet. 2018;19(1):8.
doi: 10.1186/s12881-018-0521-0 pubmed: 29329516 pmcid: 5766974
de Souza LT, Nunes RR, de Azevedo Magalhães O, Maria Félix T. A new case of osteogenesis imperfecta type VIII and retinal detachment. Am J Med Genet A. 2021;185(1):238–41.
doi: 10.1002/ajmg.a.61934 pubmed: 33098264
Sendul SY, Atilgan CU, Tiryaki S, Guven D. Bilateral papilledema in a child with osteogenesis imperfecta. Eye Vis Lond. 2016;3:25.
doi: 10.1186/s40662-016-0056-4 pubmed: 27833926 pmcid: 5066292
World Bank Open. Data. [cited 2023 Jun 4]. World Bank Open Data. https://data.worldbank.org
Ophthalmology Times. 2018 [cited 2023 Jun 4]. Corneal tomography or topography: When to make the clinical decision. https://www.ophthalmologytimes.com/view/corneal-tomography-or-topography-when-make-clinical-decision-0
Andermann A, Blancquaert I, Beauchamp S, Déry V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ. 2008;86(4):317–9.
doi: 10.2471/BLT.07.050112 pubmed: 18438522 pmcid: 2647421
Moshirfar M, Duong A, Ronquillo Y. Corneal Imaging. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Jun 5]. http://www.ncbi.nlm.nih.gov/books/NBK562157/
Asimellis G, Kaufman EJ. Keratoconus. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Jun 5]. http://www.ncbi.nlm.nih.gov/books/NBK470435/
Lagrou LM, Gilbert J, Hannibal M, Caird MS, Thomas I, Moroi SE, et al. Altered corneal biomechanical properties in children with osteogenesis imperfecta. J AAPOS. 2018;22(3):183–e1871.
doi: 10.1016/j.jaapos.2017.12.015 pubmed: 29635034
Bader J, Zeppieri M, Havens SJ. Tonometry. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Jun 5]. http://www.ncbi.nlm.nih.gov/books/NBK493225/
Watson PG, Young RD. Scleral structure, organisation and disease. A review. Exp Eye Res. 2004;78(3):609–23.
doi: 10.1016/S0014-4835(03)00212-4 pubmed: 15106941
Aubry-Rozier B, Richard C, Unger S, Hans D, Campos-Xavier B, Schneider P, et al. Osteogenesis imperfecta: towards an individualised interdisciplinary care strategy to improve physical activity and quality of life. Swiss Med Wkly. 2020;150(2728):w20285–20285.
doi: 10.4414/smw.2020.20285 pubmed: 32667677
Beckh U, Schönherr U, Naumann GOH. Autosomal dominanter Keratokonus als okuläres Leitsymptom Bei osteogenesis imperfecta Tarda Lobstein. Klin Monatsblätter Für Augenheilkd. 1995;206(04):268–72.
doi: 10.1055/s-2008-1035438
Li K, Qun W, Li X, Wang L. Limbal stem cell-sparing lamellar keratoplasty for advanced keratoglobus in a patient with osteogenesis imperfecta: a case report. Chin J Ophthalmol. 2023;59:302–4.
Rosbach J, Vossmerbaeumer U, Renieri G, Pfeiffer N, Thieme H. Osteogenesis imperfecta Und Glaukom. Ophthalmol. 2012;109(5):479–82.
Keles A, Citirik M, Sahin NM, Karaman SK, Cetinkaya S. Assessment of the retinal nerve fibre layer, retina, and choroid in osteogenesis imperfecta. Klin Monatsblätter Für Augenheilkd. 2023 Jan 12 [cited 2023 Oct 8]; http://www.thieme-connect.de/DOI/DOI?10.1055/a-1947-5339
El Halabi M, Daas L, Flockerzi F, Seitz B. Perforierende Excimerlaser-Keratoplastik Nach Akutem Keratoglobus Im Rahmen Einer Osteogenesis Imperfecta. Ophthalmol. 2023;120(7):771–5.
Trejo P, Rauch F. Osteogenesis Imperfecta in children and adolescents—new developments in diagnosis and treatment. Osteoporos Int. 2016;27(12):3427–37.
doi: 10.1007/s00198-016-3723-3 pubmed: 27492436

Auteurs

Sarah Moussa (S)

Faculty of Medicine and Health Sciences, McGill University, Montréal, Canada.

Jasmine Rocci (J)

Faculty of Medicine and Health Sciences, McGill University, Montréal, Canada.

Reggie Hamdy (R)

Faculty of Medicine and Health Sciences, McGill University, Montréal, Canada.
Shriners Hospitals for Children®-Canada, 1003, boulevard Décarie, Montréal, QC, H4A 0A9, Canada.

Jakob Grauslund (J)

Department of Ophthalmology, Odense University Hospital, Odense, Denmark.
Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Department of Ophthalmology, Vestfold Hospital Trust, Tønsberg, Norway.

Marie-Louise Lyster (ML)

Department of Endocrinology, Odense University Hospital, Odense, Denmark.

Argerie Tsimicalis (A)

Faculty of Medicine and Health Sciences, McGill University, Montréal, Canada. argerie.tsimicalis@mcgill.ca.
Shriners Hospitals for Children®-Canada, 1003, boulevard Décarie, Montréal, QC, H4A 0A9, Canada. argerie.tsimicalis@mcgill.ca.
Faculty of Medicine and Health Sciences, Ingram School of Nursing, 680 Sherbrooke Street West, H3A 2M7, Montreal, QC, Canada. argerie.tsimicalis@mcgill.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH